BIRMINGHAM, Ala., Sept. 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that executives plan to provide corporate summaries at two upcoming investor conferences.
Dr. William P. Sheridan, Chief Medical Officer of BioCryst is scheduled to present a corporate summary at the Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 2:25 p.m. Eastern Time. The conference will be held September 9-11, 2009 in New York.
Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, is scheduled to present a corporate summary at the NewsMarkers in the Biotech Industry investment conference hosted by BioCentury and ThomsonReuters in New York on Wednesday, September 16, 2009 at 2:00 p.m. Eastern Time.
Links to live audio Web casts and replays of the presentations may be accessed on the BioCryst Web site at www.biocryst.com.
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. BioCryst has discovered and progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic partnerships with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm
SOURCE BioCryst Pharmaceuticals, Inc.